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Introduction
In the second half of the 1970s, Lloyd J. Old and his group at 
Memorial Sloan-Kettering Cancer Center (MSKCC) discovered 
the first human cancer antigens by establishing an approach 
called “autologous typing.” The key preconditions of these 
discoveries were improvements in establishing human cancer 
cell lines from fresh tissue specimens and cultures from 
autologous healthy tissues, including fibroblasts and epithelial 
cells from different organs, as well as Epstein-Barr virus (EBV)-
transformed B lymphocytes.
Based on the assumption that cancer cells are recognized by 
the immune system and thus elicit a cellular and humoral 
immune response, we postulated that serum and T cells from 
cancer patients may be used as tools to identify immunogenic 
tumor-associated antigens. Because methods to generate T cell 
lines and clones in vitro were not established yet, the first 
experiments to discover tumor-associated antigens were 
performed with patients’ sera that were pre-absorbed 
extensively with autologous, allogeneic, and xenogeneic healthy 
cells. Subsequently, such sera were incubated with autologous 
cancer cells, which resulted in the discovery of a larger series of 
new human cancer antigens in different types of cancer like 
melanoma, leukemia, renal cell, brain, and others (1). As 
antibodies against these newly discovered cell surface antigens 
of human cancer generally were present in a rather low 
concentration, attempts to boost humoral immune responses in 
vivo were undertaken by vaccination with in vitro-expanded and 
lethally irradiated autologous cancer cells.
In the midst of these studies, a new era was ushered in when 
Georges Köhler and César Milstein developed a method to 
immortalize antibody-producing B cells (hybridomas) for 
which they were awarded the Nobel Prize in 1984 together with 
Niels Jerne (2). This new technique enabled the production of an 
unlimited amount of antibodies with a known and single 
specificity and opened a Pandora’s Box for the discovery of 
multiple cell surface antigens in cancer and other tissues. The 
hope for antibodies as therapeutic reagents dominated the 
decade to follow. 
In the late 1970s, methods to expand cytotoxic T lymphocytes 
(CTLs) after antigenic stimulation in vitro were developed (3, 4), 
which enabled the search for tumor-associated antigens that are 
recognized by T cells. One major advantage of T cells over 
antibodies as a discovery tool is that T cells also recognize 
antigens that are not expressed on the cell surface.
We initially focused on melanoma because we had established 
autologous sets of tumor cells and T cells mainly from this group 
of patients. At MSKCC, we started with a patient named A.V. 
who had stage IV disease (SK-MEL-29) and had been subjected 
to multiple surgical interventions without ever achieving tumor-
free surgical margins. From the blood of this patient, we 
established T cell cultures that were reactive to autologous SK-
MEL-29 melanoma cells in vitro. With the tools available at the 
time, an extensive specificity analysis was done showing tumor-
restricted reactivity at the clonal level (5). Because A.V. had the 
strongest autologous T cell reactivity of a total of 13 melanoma 
patients, whom we extensively studied over the following years, 
we interpreted the fact that he was alive and free of disease for 
more than 30 years after his initial diagnosis by cancer immune 
surveillance.
Antigen discovery - the MAGE gene family
After returning to the University of Mainz in Germany in 
1981, we identified another patient with strong T cell reactivity 
against autologous tumor cells in culture. This patient, MZ-2, 
had a stage IV amelanotic melanoma of an unknown primary 
tumor with metastatic disease to one kidney, the ovaries, lymph 
nodes, and spleen. Multiple surgical interventions followed by 
chemotherapy never achieved a complete remission.
Thierry Boon and his group at the Brussels Branch of the 
Ludwig Institute for Cancer Research (LICR) had shown in 
syngeneic murine cancer models that spontaneous non-
immunogenic tumors could be rendered immunogenic by 
mutagenesis-induced expression of tumor rejection antigens 
that were recognized by cytotoxic T cell clones. When 
challenged with the original syngeneic tumor, immune 
protection was observed (6). As most human tumors at the time 
were considered ‘non-immunogenic’ or ‘poorly immunogenic,’ 
Thierry Boon’s approach appeared as a reasonable option to be 
applied to human tumors. 
Because we had already identified T cell reactivity in two 
cancer patients, A.V. (SK-MEL-29) and MZ-2, Lloyd Old 
contacted us and suggested a collaboration between Mainz and 
Brussels. A.K. paid a first visit to the Brussels Branch in 1984 to 
present his data of autologous typing with T cell clones in 
human melanoma. This was the start of an intensive and fruitful 
collaboration over many years. 
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We generated MZ-2 melanoma cell clones and subjected these 
to in vitro mutagenesis according to the work of Thierry Boon 
and his group. Subsequently, we injected those lethally 
irradiated cells intradermally into patient MZ-2. Delayed type 
hypersensitivity (DTH) and specific T cell reactivity were closely 
monitored over many months and showed increasing DTH 
responses. A local recurrence at the site where the metastatic 
spleen had been removed occurred early during this 
intradermal vaccination period. However, before the surgeons 
could remove it, this metastasis disappeared under continued 
vaccination with autologous melanoma cell clones. As the 
vaccinations were continued at regular intervals, the detectable 
T cell reactivity increased, allowing us to derive stable tumor 
reactive T cell clones. The patient survived more than 30 years 
without ever suffering recurrent disease.
Thierry Boon and his group had just cloned murine 
mutagenesis-induced tumor rejection antigens with a T cell-
driven approach (7, 8) and then turned toward the identification 
of human tumor antigens in our MZ-2 melanoma model. In a 
first step, antigen loss variants of MZ-2 tumor cell clones were 
selected using MZ-2-derived CTLs. These loss variants were 
then transfected with MZ-2 DNA from a cosmid library 
generated from antigen-expressing MZ-2 melanoma clones. 
Transfected MZ-2 melanoma cells were tested for recognition by 
CTL clones, which led to the discovery of the MAGE (for 
melanoma antigen) gene family encoding the first human tumor 
antigen recognized by autologous T cells (9). Subsequently, 
multiple antigens were identified as targets of autologous T cells 
in the MZ-2 melanoma model. Among these are additional 
members of the MAGE gene family, as well as members of the 
BAGE and GAGE gene families (10). Analysis of the expression 
pattern of the MAGE, BAGE, and GAGE genes revealed that 
expression was only found in cancer cells and in germ cells of 
the testis, but not in any other normal tissues. After the 
discovery of more genes with a similar expression pattern, the 
term Cancer/Testis (CT) or cancer/germline family of antigens 
was later coined (11, 12).
Other T cell-defined human cancer antigens
Using similar approaches, Vincent Brichard, Aline van Pel, 
Pierre Coulie, and others of the LICR Brussels Branch identified 
and cloned the differentiation antigens tyrosinase and Melan-A 
from A.V. (SK-MEL-29) and another patient, LB39, which was a 
first indication that differentiation antigens can also be targets 
for tumor recognition and tumor rejection in human cancer (13, 
14). At the same time and independently, the same melanocyte 
differentiation antigen Melan-A was discovered by Yutaka 
Kawakami in Steven Rosenberg’s group at the National Cancer 
Institute (NCI) and was called MART-1 (15).
Thomas Wölfel and colleagues of our group in Mainz found a 
somatic mutation in the SK-MEL-29 (A.V.) melanoma that was 
efficiently targeted by A.V.’s CTLs. The antigen was a mutant 
cyclin-dependent kinase 4 (CDK4) that was insensitive to the 
tumor suppressor p16INK4a (16). Later, this mutation was found 
to occur also in the germline of melanoma families where it 
functions as a dominant oncogene due to the disrupted cell cycle 
regulation by tumor suppressor p16INK4a (17). Subsequent 
analysis of stored SK-MEL-29 (A.V.) lymphocytes uncovered 
that the majority of anti-melanoma T cells in the patient’s blood 
were specific for this particular CDK4 mutation, an arginine-to-
cysteine exchange at residue 24 (18). This in fact may have been 
a dominant tumor rejection antigen in patient A.V., who 
experienced a remarkable clinical course with long-term 
survival despite the fact that he never could be operated with 
tumor-free surgical margins. It is tempting to speculate that the 
strong and diverse T cell reactivity in both patients MZ-2 and 
A.V. kept them free of disease and saved their lives.
The SEREX technology
As technologies in molecular cloning further developed, 
Michael Pfreundschuh and his group discovered and established 
in the mid-1990s a molecular cloning technique for human 
cancer antigens by DNA expression cloning and autologous 
serum reactivity as a detection system. This serological strategy, 
termed SEREX, was a major breakthrough (19) and became a 
major tool for antigen discovery in the decade to follow, being 
employed by Pfreundschuh and his group and subsequently by 
many other researchers around the world.
The most striking experience was the fact that many of the 
antigens discovered by the tedious epitope cloning using T cells 
as a detection tool were rediscovered by the SEREX technology. 
Importantly, this indicated that antigens recognized by T cells 
may induce humoral immune responses at the same time. 
Developing a cancer vaccines program
Hans-Georg Rammensee and his group in Tübingen, 
Germany, were pioneers in the identification of minimal peptide 
epitopes for T cell recognition and their anchor residues in 
presenting MHC molecules (20). This work helped to identify 
peptide epitopes and HLA class I binding motifs from tumor 
antigens for early clinical trials that aimed to stimulate anti-
cancer immunity.
Lloyd Old had the early vision to develop a cancer 
immunotherapy program including well-controlled clinical 
trials and extensive immune monitoring. It was his mission to 
provide clinical grade reagents, and to develop and share 
standardized means of immune monitoring and clinical trials 
management with highest standards independent from 
commercial interests of industry. As CEO of the LICR, he put 
major emphasis and funds into the establishment of a 
coordinated program with selected sites all over the world for 
the development of this cancer immunotherapy program.
As affiliates, we became part of the early clinical trials program 
of the LICR with the establishment of local clinical trial centers 
at selected academic sites. We developed early intradermal 
vaccination approaches with GM-CSF as an adjuvant and DTH 
as a readout for vaccine-specific immune responses. In addition, 
the development of assays to determine cytokine expression 
patterns and T cell profiles in DTH sites were important early 
contributions to the field. It was only because of the stringent 
immune monitoring, an integral part of all clinical trials, that we 
could recognize that the solubility of antigen, recall effects with 
repeated vaccinations at different sites, and specific T cell 
induction for the immunizing antigens were important variables 
in the assessment of early cancer vaccines. 
Yao-Tseng Chen discovered the Cancer/Testis antigen NY-
ESO-1 in 1997 (21). At the time, we observed a patient, NW38, 
with strong humoral and cellular reactivity against the 
autologous tumor. As none of the tumor antigens known at the 
time appeared to be the target in this elderly patient, we checked 
for the newly discovered NY-ESO-1 as the potential target. We 
found that patient NW38 had a high level of NY-ESO-1-specific 
IgG in the blood (titers up to 1:1,000,000), as well as a strong 
NY-ESO-1-specific T cell reactivity. Subsequently, we identified 
the relevant minimal T cell epitopes and their HLA class I 
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restriction elements. In the meantime, spontaneous immune 
responses to NY-ESO-1 have been detected in many cancer 
patients with different types of cancer and, based on cumulative 
evidence, NY-ESO-1 is currently considered as one of the most 
immunogenic human cancer antigens (22). 
This knowledge prompted us to consider NY-ESO-1 as our 
first choice for cancer vaccines. The LICR and Cancer Research 
Institute (CRI) joined forces and established the Cancer Vaccine 
Collaborative in 2001 with a coordinated program of multiple 
parallel clinical trials with NY-ESO-1 as the focus. NY-ESO-1 
peptides, recombinant protein, and recombinant NY-ESO-1 
viral constructs were used alone or combined with different 
adjuvants to explore the most immunogenic method of 
therapeutic vaccination. Clinical outcomes were correlated with 
immunological findings, and several groups showed that 
favorable clinical courses of disease were associated with 
measurable immune responses, detectable intratumoral 
lymphocyte accumulation, and prolonged exposure to the 
vaccine. 
Outlook
More recently, NY-ESO-1 came to fame as a target for an 
antibody-facilitated vaccination approach against this 
intracellular cytoplasmic antigen. Hiroyoshi Nishikawa and 
colleagues discovered that a NY-ESO-1-specific antibody 
enhanced the cellular and secondary humoral immune 
responses against NY-ESO-1-expressing tumors when given 
together with chemotherapy. Importantly, the enhanced 
immune response impacted on tumor size and survival in a 
preclinical mouse model using NY-ESO-1 transfected syngeneic 
cancer cells. This discovery was recently published in Cancer 
Research and covered as a “Highlight” in the cancer literature 
(23).
As cancer patients often have high levels of antibodies against 
NY-ESO-1, and sometimes against other CT antigens as well, we 
postulated that the efficacy of conventional cancer therapies that 
release intracellular antigens, for example chemotherapy or 
radiotherapy, may be enhanced by systemic application of NY-
ESO-1-specific antibodies. A first human NY-ESO-1 antibody 
has recently been cloned from a patient with exceptionally high 
anti-NY-ESO-1 titers and a remarkably favorable clinical course. 
This human monoclonal antibody, 12D7, is currently in clinical 
development. It was Lloyd Old’s input and vision to try this new 
approach, which he liked to call Antibody-Facilitated T Cell 
Induction in Cancer (AFTIC) as a new and promising option to 
integrate cancer immunotherapy into existing treatment 
modalities in cancer.
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